These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25481272)

  • 1. HspX knock-out in Mycobacterium tuberculosis leads to shorter antibiotic treatment and lower relapse rate in a mouse model--a potential novel therapeutic target.
    Hu Y; Liu A; Menendez MC; Garcia MJ; Oravcova K; Gillespie SH; Davies GR; Mitchison DA; Coates AR
    Tuberculosis (Edinb); 2015 Jan; 95(1):31-6. PubMed ID: 25481272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of the Mycobacterium tuberculosis alpha-crystallin-like hspX gene causes increased bacterial growth in vivo.
    Hu Y; Movahedzadeh F; Stoker NG; Coates AR
    Infect Immun; 2006 Feb; 74(2):861-8. PubMed ID: 16428728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
    Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
    Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
    Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
    Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice.
    Yuan W; Dong N; Zhang L; Liu J; Lin S; Xiang Z; Qiao H; Tong W; Qin C
    Vaccine; 2012 Mar; 30(14):2490-7. PubMed ID: 21704108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterium tuberculosis ECF sigma factor sigC is required for lethality in mice and for the conditional expression of a defined gene set.
    Sun R; Converse PJ; Ko C; Tyagi S; Morrison NE; Bishai WR
    Mol Microbiol; 2004 Apr; 52(1):25-38. PubMed ID: 15049808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
    Trentini MM; de Oliveira FM; Gaeti MP; Batista AC; Lima EM; Kipnis A; Junqueira-Kipnis AP
    Vaccine; 2014 Jul; 32(34):4324-32. PubMed ID: 24951861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein.
    Shi C; Chen L; Chen Z; Zhang Y; Zhou Z; Lu J; Fu R; Wang C; Fang Z; Fan X
    Vaccine; 2010 Jul; 28(32):5237-44. PubMed ID: 20538090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants.
    Chen L; Xu M; Wang ZY; Chen BW; Du WX; Su C; Shen XB; Zhao AH; Dong N; Wang YJ; Wang GZ
    FEMS Immunol Med Microbiol; 2010 Jun; 59(1):42-52. PubMed ID: 20298499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination.
    Geluk A; Lin MY; van Meijgaarden KE; Leyten EM; Franken KL; Ottenhoff TH; Klein MR
    Infect Immun; 2007 Jun; 75(6):2914-21. PubMed ID: 17387166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis.
    Ha SJ; Jeon BY; Kim SC; Kim DJ; Song MK; Sung YC; Cho SN
    Gene Ther; 2003 Sep; 10(18):1592-9. PubMed ID: 12907951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted induction of antigen expression within dendritic cells modulates antigen-specific immunity afforded by recombinant BCG.
    Kong CU; Ng LG; Nambiar JK; Spratt JM; Weninger W; Triccas JA
    Vaccine; 2011 Feb; 29(7):1374-81. PubMed ID: 21211591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83.
    Yu DH; Hu XD; Cai H
    Gene Ther; 2008 May; 15(9):652-9. PubMed ID: 18288210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Added to Antibiotic Treatment Reduces Relapse of Disease in a Mouse Model of Tuberculosis.
    Mourik BC; Leenen PJ; de Knegt GJ; Huizinga R; van der Eerden BC; Wang J; Krois CR; Napoli JL; Bakker-Woudenberg IA; de Steenwinkel JE
    Am J Respir Cell Mol Biol; 2017 Feb; 56(2):233-241. PubMed ID: 27654457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different behaviours of promoters in Mycobacterium tuberculosis H37Rv and H37Ra.
    Dokladda K; Billamas P; Palittapongarnpim P
    World J Microbiol Biotechnol; 2015 Feb; 31(2):407-13. PubMed ID: 25556328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis.
    Aguilar LD; Infante E; Bianco MV; Cataldi A; Bigi F; Pando RH
    Vaccine; 2006 Mar; 24(13):2333-42. PubMed ID: 16388878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An experimental model of chemotherapy on dormant tuberculous infection, with particular reference to rifampicin.
    Kondo E; Kanai K
    Jpn J Med Sci Biol; 1988 Apr; 41(2):37-47. PubMed ID: 3149354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.